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OBJECTIVES: Ivabradine prevents myocardial ischemia by decreasing heart rate in
stable angina pectoris (SAP) patients. This analysis presents the cost-effectiveness
analysis of ivabradine in the treatment of SAP.METHODS: AMarkov-chain model,
in which, patients with SAP treated with ivabradine and comparators are followed
for twenty years, was built. Annual rates of revascularization, other cardiovascular
events and mortality were calculated. Direct costs were taken into account from
the perspective of social security institution. Randomized clinical studies, other
comparative studies andmeta-analysis were taken as sources of inputs. RESULTS:
Annual revascularization rate was 5.0% for ivabradine and 6.5-7.0% for compara-
tors. Estimated number of revascularizations within 20 years was 120 procedures
per 100 patients with ivabradine as compared to 135-139 with others. Annual car-
diovascular event rate was 7.5% for ivabradine and 10.4-10.9% for comparators.
Total number of cardiovascular events within 20 years was 151 events per 100
patients with ivabradine as compared to 207-219 with others. Duration of event-
free life years was 9.9 years with ivabradine and 7.7-8.1 years with others. Incre-
mental Cost Effectiveness Ratio for ivabradine decreased down to cost-effective-
ness threshold (three times GDP per capita per one event-free life year) within the
first year versus isosorbide mononitrate and verapamil, and in the second year
versus amlodipine and diltiazem. Annual mortality rate was 1.7% with ivabradine,
while it was 2.2%with comparators. Life-years gained per 20 years with ivabradine
was 0.8 years (16.4 vs 15.7 with ivabradine and with comparators, respectively).
CONCLUSIONS:When savings provided by the decreases in revascularization and
cardiovascular event rates are taken into account, annual treatment cost differ-
ence between ivabradine and other drugs decreases. Longer life years and event-
free life years provided by ivabradine makes it a cost effective choice for SAP.
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EFFECTIVENESS OF DISEASE MANAGEMENT CARE IN THE CASE OF HEART
FAILURE
Ugiliweneza B
University of Louisville, Louisville, KY, USA
OBJECTIVES: The main objective of this study was to evaluate the cost effective-
ness of the managed care in the case of heart failure. Also, the proportion of pa-
tients with a hospital free year was compared using managed care and non-man-
aged care the non-managed care.METHODS:Ameta-analysiswas used to estimate
the effectiveness (hospital free years). Cost effectiveness was analyzed in two per-
spectives: the program’s and the payer’s. In the program’s perspective, the litera-
ture was used to estimate the cost. In the payer’s perspective, Thomson Reuter’s
MarketScan datawere used to estimate the cost. RESULTS: It was found that, in the
program’s perspective, a hospital free year’s cost was $8,872.60while in the payer’s
perspective by using managed care; it saved an average of $53,109.22. The propor-
tion of individuals with a hospital free year in managed care and in the usual care
were not found to be statistically significant. CONCLUSIONS: Even though man-
aged care did not have a different hospitalization usage than standard care, it was
found to be cost-effective for the payer.
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COST-MINIMIZATION ANALYSIS OF THROMBOPROPHYLAXIS FOLLOWING
ELECTIVE TOTAL HIP ARTHROPLASTY
Delate T, Clark N, Cho S, Witt D
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OBJECTIVES: Tomodel the costs of thromboprophylaxis following total hip arthro-
plasty (THA) with either low-intensity warfarin, enoxaparin, or fondaparinux.
METHODS: This was a cost-minimization analysis of anticoagulants expected to
have equivalent tolerability and effectiveness. Data were obtained from an HMO’s
joint replacement registry. Patients were included if they had THA between August
2005 and March 2009, continuous enrollment in the 180 days prior to and 90 days
following THA, utilized low-intensity warfarin thromboprophylaxis, and had not
been chronically anticoagulated previously. Patients received warfarin therapy su-
pervised through a pharmacist-run anticoagulation service that included mobile
phlebotomy for INR monitoring. Iterative modeling from the HMO’s perspective
utilized registry data to calculate the costs of thromboprophylaxis with anticoag-
ulants at 2010 AWPminus 35%,monitoring at $50 per phlebotomy, $15 per INR, and
0.1 hour pharmacist time (at $75/hr) per INR. Patient training for any anticoagulant
use was included at 0.25 hr pharmacist time. Duration of therapy was modeled to
a mean of 35 days for injectible (enoxaparin and fondaparinux) thromboprophy-
laxis for which monitoring services would not be required. Sensitivity analyses
included reducing AWPs by 25% prior to discounting and increasing phlebotomy
and INRs to $75 and $25, respectively. RESULTS: 835 THAs for 800 patients were
included. The mean age and duration warfarin therapy were 66 years and 40 days,
respectively, and 62% were females. The base-case thromboprophylaxis cost was
$556 (95% CI$545-$567), $701 (95% CI$693-$709), and $2677 (95% CI$2646-
$2708) for warfarin, enoxaparin, and fondaparinux, respectively. 25% AWP reduc-
tion resulted in thromboprophylaxis costs of $553 (95% CI$542-$564), $564 (95%
CI$558-$571), and $2145 (95% CI$2120-$2171) for warfarin, enoxaparin, and
fondaparinux, respectively. Increasing monitoring costs resulted in thrombopro-
phylaxis cost of $756 (95% CI$740-$771) for warfarin. CONCLUSIONS: Warfarin
thromboprophylaxis had the lowest cost but is sensitive to monitoring costs
whereas injectible thromboprophylaxis is sensitive to drug acquisition costs.
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OBJECTIVES: To conduct a cost-minimization analysis of landiolol for CT diagnosis
of cardiovascular diseases (CVD) suspicious patient with tachycardia in Japan.
METHODS: A decision-tree model was constructed to analyze costs from health-
care payer’s perspective. Drug costs and diagnosis costs, computer tomography
(CT) and coronary angiography (CAG),are adopted to themodel. Landiolol is admin-
istered only to slow the heart rate to take CT image appropriately. Since some trials
proved that there was no difference between landiolol and placebo in terms of
efficacy and safety, we conducted cost-minimization analysis. 22.4% of those who
suspicious for CVD are thought to be take beta-blockers. Success rate for CT scan-
ning for landiolol andplacebo, derived fromdomestic trial data,were 81.4% (96/118,
77.8% - 84.9%) and 54.2% (64/118, 49.7% - 58.8%). Patients who failed to take CT
image were thought to take CAG. The healthcare cost were derived from Japanese
data costs of landiolol, CT imaging, CAG are JPY6,500 (USD79, USD1JPY82.7),
JPY39,100 (USD472) and JPY 105,900 (USD1,279), respectively. Positive rate for CAG,
derived from domestic trial data, were 37.1% (33/89, 32.0% - 42.2%). Various sensi-
tivity analyses, both univariate and probabilistic ones, were conducted. RESULTS:
In the basecase analysis, expected costs per patient for landiolol and placebo were
JPY82,600 (USD998) and JPY85,218 (USD1,029), respectively. In budget impact anal-
ysis, 49,000 patients are eligible for landiolol and it can save JPY 120mil.
(USD1.45mil.) for whole patients. Sensitivity analyses suggested the robustness of
the results. CONCLUSIONS: Landiolol for CT diagnosis of cardiovascular diseases
(CVD) suspicious patient with tachycardia is thought to be cost-saving.
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OBJECTIVES: T2DM is a chronic metabolic disorder characterized by hyperglyce-
mia and associated with significant morbidity. This may be particularly so among
patients with pre-existingmacrovascular conditions (MVC). This study was under-
taken to differentiate healthcare resource utilization between T2DM patients with
and without pre-existing MVC in Europe. METHODS: This is a matched cohort
study based on the Real-Life Effectiveness and Care Patterns of Diabetes Manage-
ment (RECAP-DM) study, a multi-center, observational study with retrospective
medical chart reviews of T2DM patients in eight European countries. Included
patients were aged30 year at time of diagnosis of T2DM and added a SU or a TZD
to failing metformin monotherapy (index date), and had pre-existing (i.e., with
onset date prior to index date) MVC. A control cohort with T2DM but without
pre-existing MVCwas identified using 1:1 propensity scorematching. Logit models
were used to identify the relationship between pre-existingMVC and the likelihood
of ER admission, receivingmedical/surgical procedures, and hospitalization during
the study period. Negative binomial models were used to predict the number of
office visits and length of hospital stay per year attributable to the pre-existing
MVC.RESULTS:Of the 453 eligible patientswith pre-existingMVC (cases), 64%were
male, mean age and time from T2DM diagnosis was 64.5 (9.1) and 6.2 (5.3) years,
respectively. HbA1c prior to the index date was 8.0 (1.2). Relative to controls, pa-
tientswith pre-existingMVCwere significantlymore likely to report ER admissions
(Odds Ratio 3.1; 95%CI 1.8-5.2), receiving medical/surgical procedures (OR 2.72;
95%CI 1.7-4.3), and hospitalizations (OR 2.6; 95%CI 1.7-4.0) after controlling for
other predictors. Similarly, pre-existing MVC incurred 2.9 additional office visits
per year (p0.001) and 0.41 days of hospital stay per year (p0.004).CONCLUSIONS:
This study found that T2DMpatientswith pre-existingMVCweremore likely to use
various types of healthcare resources.
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OBJECTIVES: To determine association between heart failure (HF) and resource
utilization in ST-elevationmyocardial infarction (STEMI) patients treated with Per-
cutaneous Coronary Intervention (PCI).METHODS: Retrospective analysis of I3 In-
Vision Data Mart (2003-08). Adult enrollees (18 years) with primary diagnosis of
STEMI were selected if they were a) treated using PCI procedure and b) had contin-
uous enrollment for at least 6 months prior (baseline) to the STEMI-related index
hospitalization. Enrollees were excluded if they underwent coronary artery bypass
graft during index hospitalization. Pre-existing HF was defined as presence of a
claim comprising relevant HF diagnosis at baseline. New onset HF was defined as
listing of HF as comorbidity in the reimbursement claims for index hospitalization
without supporting evidence for pre-existing HF at baseline. General and general-
ized linear models were used to assess impact of HF (versus no HF) on resource
utilization parameters including length of stay (LOS) and on costs (log-trans-
formed) associated with STEMI-related index hospitalization, respectively. Priori
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significance level of 0.05 was used for these analyses. RESULTS: Overall 7,261 en-
rolleeswere included in the analysis. Out of these, 187 (2.6%) hadHF at baseline and
1,075 (14.8%) experienced HF for the first time. Mean LOS was 4.29 (7.5) days but
increased significantly to 8.8 (17.6) days in case of new onset HF (  5.20.2,
p0.001) and to 9.7 (10.5) days if pre-existing HF was included as a major comor-
bidity (  6.00.7, p0.001) during index hospitalization. Hospitalization costs
(log-transformed) were associated with recording of new onset HF (  0.40.02,
p0.001) but not with reporting of pre-existing HF (  0.10.1, p0.1451) as a
comorbid condition during index hospitalization.CONCLUSIONS:Newonset of HF,
recorded as a major comorbid condition, in STEMI patients undergoing PCI exhib-
ited significant independent association with resource utilization including in-
creased length of stay and greater costs.
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PERSISTENCE AND COMPLIANCE IN HYPERTENSIVE PATIENTS TREATED WITH
FIXED OR UNFIXED COMBINATIONS OF ANGIOTENSIN RECEPTOR BLOCKERS,
AMPLODIPINE AND HYDROCHLOROTHIAZIDE
Sandberg A1, Kostev K2, Ehlken B3, Holz B2, Oberdiek A1
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OBJECTIVES: To evaluate persistence and compliance of fixed dose combinations
in comparison to unfixed dose combinations of angiotensin receptor blockers
(ARBs) in patients with hypertension in Germany. METHODS: This retrospective
study analyzed prescription data collected by general practitioners, using a longi-
tudinal database, the German IMS Disease Analyzer (DA). The DA database was
searched for patients with hypertension (ICD-10 code I10) who were initiated on
double or triple combinations of ARBs with hydrochlorothiazide (HCT) and/or am-
lodipine (AML) in the period 09/2008-08/2009with a follow-up of at least 12months.
Persistence was defined as proportion of patients who remained on their initially
prescribed therapy at 1 year. The difference between mean persistence values
(days) were calculated by using multiple regression analyses adjusted by age, gen-
der, region, insurance and co-morbidity. Compliance was measured indirectly
based on the medication possession ratio calculated as number of days supplied
within the refill interval in relation to the number of days in the refill interval.
RESULTS:Overall, 17,310 patientswere eligible for analysis: 35.7% on a fixed double
ARB combination, 33.0% on an unfixed double ARB combination, 25.9% on a semi-
fixed triple ARB combination, and 5.4% on an unfixed triple ARB combination.
Twelve months after first prescription persistence on unfixed versus semi-fixed
ARB/HCTAML triple combination was 32.7% and 46.7 % respectively, unfixed ver-
sus semi-fixed ARB/AMLHCT triple combination was 41.5% and 49.0% respec-
tively, unfixed versus fixed ARB/HCT double combination 23,8% and 41.1% respec-
tively, unfixed versus fixed ARB/AML double combination 27.5% and 44.4%
respectively. Mean days of persistence was higher in patients receiving fixed com-
binations (225.7-242.9) compared to unfixed combinations (163.6-228.0). Mean
compliance value with fixed combinations ranged between 72.0%-79.0%, with un-
fixed combinations between 71.5-76.2%. CONCLUSIONS: These real-life data con-
firms previous study results, that fixed combinations improve persistence in pa-
tients compared to unfixed combinations because of reduced pill burden.
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OBJECTIVES: Compare statin adherence, persistence, and health care costs among
patients in whom atorvastatin (AS), simvastatin (SS), rosuvastatin (RS), or prava-
statin (PS) was newly prescribed.METHODS: Study patients 18 years were iden-
tified betweenOctober 1, 2006-September 30, 2007, with aminimum12-month pre-
and 24-month post-index health plan eligibility from a managed care database. A
6-month washout period free of any statin use was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription and four cohortswere created based on index statins:
AS, SS, RS, and PS. These cohorts were matched according to propensity scores
based on patient clinical and demographic characteristics. Outcomes were com-
pared among matched cohorts during the 2-year post-index period, including ad-
herence to any statin (medication possession ratio0.8), time to any statin discon-
tinuation, and health care costs. RESULTS: After matching, 6185 patients were
obtained in each cohort and the baseline characteristics were balanced among
cohorts. Half of the patients were adherent to their statin therapy at 12 months
(52.2% for SS, 47.3% for AS, 48.6% for RS, and 49.7% for PS, P0.01), with further
decline at 24 months (43.1% for SS, 38.0% for AS, 39.2% for RS, and 38.5% for PS,
P0.01). Median time to any statin discontinuation within 24 months were less
than 1 year for all cohorts (SS: 308 days; AS: 250 days; RS: 266 days; PS: 301 days,
P0.01). The cohorts had slightly different 2-year health care costs (SS: $15,417; AS:
$16,826; RS: $15,874; PS: $15,481, P0.01) with the most difference attributable to
the lower drug costs (SS: $4460; AS: $5485; RS: $5424; PS: $4586, P0.01).
CONCLUSIONS: Patients had low adherence and persistence rates to statin ther-
apy. Patients initiating different statins had varying adherence and persistence
profiles, including 2-year health care costs.
PCV61
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BENEFICIARIES TAKING STATIN MEDICATION
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OBJECTIVES: The objective was to determine the impact of Medicare part D dough-
nut hole or the ‘coverage gap’ on medication compliance behavior and healthcare
resource utilization among Medicare beneficiaries taking statin medications.
METHODS: This was a retrospective cohort study using a 2007 5% National sample
of Medicare beneficiaries. Beneficiaries enrolled in the Part D programwith at least
1 prescription claim for statin were included in the study. Patients were classified
as continuers, switchers and discontinuers of statinmedications after reaching the
coverage gap. The primary outcomes of interest were average number of emer-
gency room (ER) visits, hospitalizations, out of pocket (OoP) costs and number of
prescriptions pre and post coverage gap. RESULTS: 131237 patients met the inclu-
sion criteria. All patients in the study sample were diagnosedwith hyperlipidemia,
and 8,251 patients were prescribedwith statins as a primary prevention treatment.
Of the beneficiaries taking statins, 65.8% were female; 80.71% white; 10.91% black
and themean age was 71.9 (12.0) years. Overall, 24.3% of statin users reached the
coverage gap in 2007, with 10.2% reaching the gap by March, 42.0% by June, and
74.4% by September. Within 90 days after reaching the gap, 74.2% of statin users
continued using their statin medication, 1.0% switched to a different statin medi-
cation, and 24.8% discontinued use of statins. After reaching the coverage gap, the
average number of ER visits/month increased from 0.24 to 0.25 and the average OoP
costs/month increased from $58.51 to $104.03. CONCLUSIONS: The results suggest
an overall negative impact of the Medicare part D coverage gap on enrollee health,
adherence to statin medications, number of hospitalizations, emergency depart-
ment visits and out of pocket expenses incurred by beneficiaries. The disruption of
the coverage gap on the quality of care is demonstrated by the large percentage of
statin users discontinuing therapy.
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OBJECTIVES:To evaluate treatment compliance and persistence in patients receiv-
ing fixed combinations compared to patients receiving unfixed combinations with
olmesartan medoxomil for hypertension treatment in Germany. METHODS: This
retrospective study analyzed prescription data collected by general practitioners,
using a longitudinal database, the German IMS Disease Analyzer (DA). The DA
database was searched for patients with hypertension (ICD-10 code I10) who were
initiated on double or triple combinations of olmesartan medoxomil with hydro-
chlorothiazide and/or amlodipine in the period 09/2008-08/2009with a follow-up of
at least 12 months. Persistence was defined as proportion of patients who re-
mained on their initially prescribed therapy at 1 year. The difference between
mean persistence values (days) were calculated by using multiple regression anal-
yses adjusted by age, gender, region, insurance and co-morbidity. Compliance was
measured indirectly based on the medication possession ratio calculated as num-
ber of days suppliedwithin the refill interval in relation to thenumber of days in the
refill interval. RESULTS: In total, 7,360 patients were eligible for analysis, 58.0%
were treated with a fixed or semi-fixed combination of olmesartan and 42.0% with
a dual or triple unfixed combination of olmesartan. After 12 months following the
first prescription, fixed or semi-fixed combinations had a higher rate of persistence
(43.4%-50.2%) compared to dual or triple unfixed combinations (25.0%-35.8%).Mean
duration of persistence was higher in patients receiving dual or triple fixed or
semi-fixed combinations (222.5-242.7 days) compared to patients receiving unfixed
combinations (183.6-205.0 days). Mean compliance value with olmesartan in all
combinations ranged between 70.0% 80.0%. CONCLUSIONS: Overall, persistence
is increased in patients receiving fixed combinations of olmesartan in comparison
to free combinations. These real-life data confirms previous study results, that
persistence of fixed combinations in comparison to unfixed combinations is im-
proved because of reduced pill burden.
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THE IMPACT OF CARDIOVASCULAR DISEASE HOSPITALIZATIONS ON CHANGES
IN PATIENT ADHERENCE TO ANTIHYPERTENISVE DRUGS IN A MEDICAID
POPULATION
Yan X, Shaya FT
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: The impact of health behaviors (e.g., medication adherence) on out-
comes (e.g., hospitalizations) has been widely explored in literature, but few stud-
ies have evaluated the reverse association. We investigated the impact of cardio-
vascular disease (CVD) hospitalizations on changes in adherence to
antihypertensive (AH) drugs.METHODS:Maryland Medicaid claims data from Jan-
uary 2001 to June 2006 were analyzed. The index date for patients with a CVD
hospitalization was the admission date of the first observed CVD-related hospital-
ization. Matched controls had the same index date as index patients. Proportion of
days covered (PDC) was used to measure medication adherence (adherence:
PDC80%). Patients with and without a CVD hospitalization were matched 1:1, on
the first pharmacy claim (6month) of any AH drugs recorded in the database, age
(5 years), gender, race, number of drugs taken in the 6-month pre-index period
(1 drug), and adherence rate to AH drugs in the 6-month pre-index period (5%
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